We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will 2020 MAP to Growth Initiative Drive RPM's Q3 Earnings?
Read MoreHide Full Article
RPM International Inc. (RPM - Free Report) is scheduled to report third-quarter fiscal 2020 results on Apr 8, before the opening bell.
In the last reported quarter, the company’s top and bottom lines surpassed the Zacks Consensus Estimate by 0.3% and 4.1%, and improved 2.8% and 31% on a year-over-year basis, respectively. The upside was driven by the 2020 MAP to Growth initiative, strong pricing and moderate raw material inflation.
Trend in Estimate Revision
The Zacks Consensus Estimate for fiscal third-quarter earnings per share has been unchanged at 20 cents over the past 60 days. This indicates an increase of 42.9% from the year-ago reported figure of 14 cents per share. The consensus mark for revenues is $1.18 billion, suggesting a 3.4% year-over-year improvement.
RPM is likely to have witnessed modest year-over-year sales growth in the fiscal third quarter, which is a seasonally weak period, supported by solid inorganic moves and growth across the business.
The company expects revenues, adjusted EBIT and earnings to be at the higher end of its previously announced guidance for the fiscal third quarter. It projects revenue growth in the range of 2.5-4%. It also anticipates adjusted EBIT growth within 25-30% and adjusted earnings in the high-teens to low-20-cent range.
RPM’s focus on strategic acquisitions to drive top-line growth and gain market share bodes well. Also, its 2020 MAP to Growth operating improvement plan — comprising efforts to reduce costs by closing plants, merging IT system, centralizing more of its back-office functions and rationalizing manufacturing footprint — is likely to have boosted bottom-line performance in the to-be-reported quarter.
RPM’s supply chain and business operations remain strong amid the COVID-19 outbreak. Moreover, management has revealed that the company intends to meet the changing needs of customers in this unprecedented period. Although negative impact of foreign currency translation, and higher costs and expenses are likely to have been pressing concerns, cost-saving initiatives are expected to have helped it offset these woes.
What Our Model Indicates
Our proven model does not conclusively predict an earnings beat for RPM this time around. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. Unfortunately, that is not the case here, as you will see below.
Earnings ESP: Earnings ESP for RPM is -0.83%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some companies in the Zacks Construction sector, which according to our model have the right combination of elements to post an earnings beat in their respective quarters to be reported.
Louisiana-Pacific Corporation (LPX - Free Report) has an Earnings ESP of +10.11% and holds a Zacks Rank #3.
MasTec, Inc. (MTZ - Free Report) has an Earnings ESP of +11.97% and a Zacks Rank #3.
Quanta Services, Inc. (PWR - Free Report) has an Earnings ESP of +4.31% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Will 2020 MAP to Growth Initiative Drive RPM's Q3 Earnings?
RPM International Inc. (RPM - Free Report) is scheduled to report third-quarter fiscal 2020 results on Apr 8, before the opening bell.
In the last reported quarter, the company’s top and bottom lines surpassed the Zacks Consensus Estimate by 0.3% and 4.1%, and improved 2.8% and 31% on a year-over-year basis, respectively. The upside was driven by the 2020 MAP to Growth initiative, strong pricing and moderate raw material inflation.
Trend in Estimate Revision
The Zacks Consensus Estimate for fiscal third-quarter earnings per share has been unchanged at 20 cents over the past 60 days. This indicates an increase of 42.9% from the year-ago reported figure of 14 cents per share. The consensus mark for revenues is $1.18 billion, suggesting a 3.4% year-over-year improvement.
RPM International Inc. Price and EPS Surprise
RPM International Inc. price-eps-surprise | RPM International Inc. Quote
Factors Supporting Growth
RPM is likely to have witnessed modest year-over-year sales growth in the fiscal third quarter, which is a seasonally weak period, supported by solid inorganic moves and growth across the business.
The company expects revenues, adjusted EBIT and earnings to be at the higher end of its previously announced guidance for the fiscal third quarter. It projects revenue growth in the range of 2.5-4%. It also anticipates adjusted EBIT growth within 25-30% and adjusted earnings in the high-teens to low-20-cent range.
RPM’s focus on strategic acquisitions to drive top-line growth and gain market share bodes well. Also, its 2020 MAP to Growth operating improvement plan — comprising efforts to reduce costs by closing plants, merging IT system, centralizing more of its back-office functions and rationalizing manufacturing footprint — is likely to have boosted bottom-line performance in the to-be-reported quarter.
RPM’s supply chain and business operations remain strong amid the COVID-19 outbreak. Moreover, management has revealed that the company intends to meet the changing needs of customers in this unprecedented period. Although negative impact of foreign currency translation, and higher costs and expenses are likely to have been pressing concerns, cost-saving initiatives are expected to have helped it offset these woes.
What Our Model Indicates
Our proven model does not conclusively predict an earnings beat for RPM this time around. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. Unfortunately, that is not the case here, as you will see below.
Earnings ESP: Earnings ESP for RPM is -0.83%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently has a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks With Favorable Combination
Here are some companies in the Zacks Construction sector, which according to our model have the right combination of elements to post an earnings beat in their respective quarters to be reported.
Louisiana-Pacific Corporation (LPX - Free Report) has an Earnings ESP of +10.11% and holds a Zacks Rank #3.
MasTec, Inc. (MTZ - Free Report) has an Earnings ESP of +11.97% and a Zacks Rank #3.
Quanta Services, Inc. (PWR - Free Report) has an Earnings ESP of +4.31% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>